公开(公告)号：US10507201B2

公开(公告)日：2019-12-17

申请号：US16289612

申请日：2019-02-28

Applicant: NOVARTIS AG

Inventor： Nicole Buschmann ,  Robin Alec Fairhurst ,  Pascal Furet ,  Diana Graus Porta ,  Carolina Haefliger ,  Bo Han ,  Thomas Knöpfel ,  Catherine Leblanc ,  Lv Liao ,  Robert Mah ,  Masato Murakami ,  Pierre Nimsgern ,  Michael Palmer ,  Dale Porter ,  Sebastien Ripoche ,  Can Wang ,  Youzhen Wang ,  Andreas Weiss ,  Jing Xiong ,  Xianglin Zhao

IPC: A61K31/475 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/55 ,  A61P35/00 ,  A61K31/4375

Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof

公开(公告)号：US20190105309A1

公开(公告)日：2019-04-11

申请号：US16211139

申请日：2018-12-05

Applicant: Novartis AG

Inventor： Nicole Buschmann ,  Robin Alec Fairhurst ,  Pascal Furet ,  Thomas Knoepfel ,  Catherine Leblanc ,  Robert Mah

IPC: A61K31/444 ,  A61K31/497 ,  A61P35/00

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

公开(公告)号：US09051279B2

公开(公告)日：2015-06-09

申请号：US13778910

申请日：2013-02-27

Applicant: Novartis AG

Inventor： Joerg Berghausen ,  Nicole Buschmann ,  Pascal Furet ,  Francois Gessier ,  Joanna Hergovich Lisztwan ,  Philipp Holzer ,  Edgar Jacoby ,  Joerg Kallen ,  Keiichi Masuya ,  Carole Pissot Soldermann ,  Haixia Ren ,  Stefan Stutz

IPC: C07D239/82 ,  A01N43/54 ,  A61K31/517 ,  C07D217/24 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

CPC classification number: C07D239/82 ,  C07D217/24 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) wherein Z is CH2 or N—R4 and X, R1, R2, R4, R6, R7 and n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.

Abstract translation: 本发明涉及式（I）的取代的含氮双环杂环，其中Z是CH 2或N-R 4，X，R 1，R 2，R 4，R 6，R 7和n如说明书中所定义。 这些化合物适用于治疗由MDM2和/或MDM4或其变体的活性介导的病症或疾病。

公开(公告)号：US10786492B2

公开(公告)日：2020-09-29

申请号：US16211139

申请日：2018-12-05

Applicant: Novartis AG

Inventor： Nicole Buschmann ,  Robin Alec Fairhurst ,  Pascal Furet ,  Thomas Knoepfel ,  Catherine Leblanc ,  Robert Mah

IPC: C07D401/12 ,  C07D401/14 ,  A61K31/444 ,  A61K31/4427 ,  C07D213/75 ,  C07D405/14 ,  A61P35/00 ,  A61K31/497

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

公开(公告)号：US10130629B2

公开(公告)日：2018-11-20

申请号：US15561209

申请日：2016-03-23

Applicant: Novartis AG

Inventor： Nicole Buschmann ,  Robin Alec Fairhurst ,  Jorge Garcia Fortanet ,  Pascal Furet ,  Diana Graus Porta ,  Nafeeza Hafeez ,  Bo Han ,  Thomas Knoepfel ,  Matthew J. LaMarche ,  Catherine Leblanc ,  Lv Liao ,  Robert Mah ,  Dale Porter ,  Can Wang ,  Markus Wartmann ,  Jing Xiong ,  Xianglin Zhao

IPC: A61K31/496 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377

Abstract: A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.